Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Edesa Biotech stock

Own Edesa Biotech stock in just a few minutes.

Edesa Biotech, Inc is a biotechnology business based in the US. Edesa Biotech shares (EDSA) are listed on the NASDAQ and all prices are listed in US Dollars. Edesa Biotech employs 12 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Edesa Biotech

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EDSA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Edesa Biotech share price

Use our graph to track the performance of EDSA stocks over time.

Edesa Biotech shares at a glance

Information last updated 2021-04-29.
52-week range$2.20 - $10.15
50-day moving average $5.51
200-day moving average $5.66
Wall St. target price$17.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-5.79

Buy Edesa Biotech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Edesa Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Edesa Biotech financials

Revenue TTM $221,001
Gross profit TTM $311,200
Return on assets TTM -64.28%
Return on equity TTM -117.23%
Profit margin 0%
Book value $0.56
Market capitalisation $79.7 million

TTM: trailing 12 months

Shorting Edesa Biotech shares

There are currently 78,102 Edesa Biotech shares held short by investors – that's known as Edesa Biotech's "short interest". This figure is 11.9% down from 88,602 last month.

There are a few different ways that this level of interest in shorting Edesa Biotech shares can be evaluated.

Edesa Biotech's "short interest ratio" (SIR)

Edesa Biotech's "short interest ratio" (SIR) is the quantity of Edesa Biotech shares currently shorted divided by the average quantity of Edesa Biotech shares traded daily (recently around 251941.93548387). Edesa Biotech's SIR currently stands at 0.31. In other words for every 100,000 Edesa Biotech shares traded daily on the market, roughly 310 shares are currently held short.

However Edesa Biotech's short interest can also be evaluated against the total number of Edesa Biotech shares, or, against the total number of tradable Edesa Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Edesa Biotech's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Edesa Biotech shares in existence, roughly 10 shares are currently held short) or 0.01% of the tradable shares (for every 100,000 tradable Edesa Biotech shares, roughly 10 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Edesa Biotech.

Find out more about how you can short Edesa Biotech stock.

Edesa Biotech share dividends

We're not expecting Edesa Biotech to pay a dividend over the next 12 months.

Have Edesa Biotech's shares ever split?

Edesa Biotech's shares were split on a 1:6 basis on 9 June 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Edesa Biotech shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Edesa Biotech shares which in turn could have impacted Edesa Biotech's share price.

Edesa Biotech overview

Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Frequently asked questions

What percentage of Edesa Biotech is owned by insiders or institutions?
Currently 33.031% of Edesa Biotech shares are held by insiders and 14.876% by institutions.
How many people work for Edesa Biotech?
Latest data suggests 12 work at Edesa Biotech.
When does the fiscal year end for Edesa Biotech?
Edesa Biotech's fiscal year ends in September.
Where is Edesa Biotech based?
Edesa Biotech's address is: 100 Spy Court, Markham, ON, Canada, L3R 5H6
What is Edesa Biotech's ISIN number?
Edesa Biotech's international securities identification number is: CA27966L1085
What is Edesa Biotech's CUSIP number?
Edesa Biotech's Committee on Uniform Securities Identification Procedures number is: 27966L108

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site